Group 1 - The company, Chengda Biological, announced the establishment of a biomedical industry investment fund in collaboration with its controlling shareholder, Liaoning Chengda, and its subsidiaries, aiming to enhance its competitive edge and capitalize on opportunities in the biopharmaceutical industry [1][2] - The total scale of the fund is set to not exceed 100 million yuan, with an initial size of 50.2 million yuan. The fund will be managed by Chengda Coastal, which will contribute 1 million yuan, representing approximately 0.1992% of the initial fund size [1] - Chengda Biological plans to contribute 40 million yuan, accounting for about 79.6813% of the initial fund size, while Liaoning Chengda will contribute 10 million yuan, representing approximately 19.9203% [1] Group 2 - The fund will focus on investments in the life and health sector during its investment period, with further capital contributions expected to reach the total commitment of 100 million yuan within three years [2] - The fund is currently in the planning stage, and the partnership agreement has not yet been formally signed, meaning that the investment shares are subject to the final agreement [2] - The company's board of directors has proposed to authorize the management to handle all matters related to this external investment, including timely progress on the fund's establishment and registration [2]

Core Viewpoint - Liaoning Chengda (600739.SH) plans to establish a biopharmaceutical investment fund to enhance its competitiveness and seize market opportunities, with a total fund size not exceeding 100 million yuan, and an initial size of 50.2 million yuan [1][2] Group 1: Fund Structure and Contributions - The fund will be managed by Chengda Coastal as the general partner, contributing 1 million yuan, which accounts for 0.1992% of the initial fund size [1] - Shenzhen Chengda Biotech will also act as a general partner, contributing 1 million yuan, representing 0.1992% of the initial fund size [1] - Liaoning Chengda will contribute 10 million yuan as a limited partner, making up 19.9203% of the initial fund size [1] - Chengda Biotech will contribute 40 million yuan as a limited partner, accounting for 79.6813% of the initial fund size [1] Group 2: Fund Investment Focus and Future Plans - The fund will focus on the life and health industry during its investment period, with plans to raise the total contribution to 100 million yuan within three years [2] - Shenzhen Chengda Biotech and Chengda Medical plan to increase their investment in Gene Qiming, with Shenzhen Chengda Biotech contributing 40 million yuan and Chengda Medical contributing 10 million yuan [2] - After the fund is legally established, it will acquire all shares of Gene Qiming held by Shenzhen Chengda Biotech and Chengda Medical, allowing the company to indirectly enjoy related rights through the fund [2]

Core Viewpoint - Liaoning Chengda (600739.SH) plans to establish a biopharmaceutical investment fund to enhance its competitiveness and seize market opportunities, with a total fund size not exceeding 100 million yuan, and an initial size of 50.2 million yuan [1][2] Group 1: Fund Structure and Contributions - The fund will be managed by Chengda Coastal as the general partner and will have contributions from various subsidiaries, with Liaoning Chengda contributing 10 million yuan (19.92% of the initial fund) and Chengda Biological contributing 40 million yuan (79.68% of the initial fund) [1] - Chengda Coastal and Shenzhen Chengda Biological will each contribute 1 million yuan, representing approximately 0.1992% of the initial fund [1] Group 2: Fund Focus and Future Plans - The fund will focus on the life and health sector during its investment period, with plans to raise the total contributions to 100 million yuan within three years [2] - Shenzhen Chengda Biological and Chengda Medical plan to increase their investment in Gene Qiming, with contributions of 40 million yuan and 10 million yuan respectively, to be transferred to the fund after its establishment [2]